The traditional classification of membranoproliferative glomerulonephritis (MPGN) based on morphology has been replaced with a more scientifically acceptable etiopathological classification.
The pathogenesis similar to atypical hemolytic uremic syndrome (aHUS) involves specific complement protein deficiencies or antibodies against complement stabilizing components which leads to tick over in the alternate complement pathway. The similar pathophysiology of C3G and aHUS prompted the work on eculizumab for C3G. However, in contrast to aHUS, the response has been heterogeneous. [3] Complement activation with endothelial damage by complexes is the underlying pathogenic mechanism in aHUS, whereas deposition of the C3-cleaved products in the glomeruli is the problem in C3G. The upstream C3 cleaving is probably not interrupted by eculizumab which is C5 cleavage inhibitor, explaining the poor response to this form of therapy. Furthermore, the economic considerations limit the widespread use of this drug in the middle-income countries. Complement-mediated glomerulopathy is debilitating as it affects young adults, and the progression to end-stage kidney disease is much faster (29% reach end-stage renal disease in a mean follow-up of 28 months). [4] Poor survival outcomes of this young cohort on dialysis make transplant a necessary but risky option. The reported recurrence rate is as high as 50%-100%. [5] The scientific evidence in the literature regarding the management of recurrent posttransplant C3G is scarce. Zand et al. reported a series of 14 patients with C3G recurrence. [6] A single patient in this series received plasmapheresis with partial response. McCaughan et al. reported promising response with eculizumab, but the economic and availability concerns can be a huge deterrent for this drug. [7] Pipeleers et al. reported the use of aggressive plasmapheresis immediate posttransplant followed by long-term maintenance twice monthly as a method to prevent recurrent C3G posttransplant. [8] Although newer and innovative therapies such as soluble complement receptor 1 which act as complement regulators have shown some promise in native disease, their role in posttransplant recurrence is unknown.
The rarity of disease and economic burden of management contributed to the lack of large scale studies in literature. The reference study [9] tried to look into the therapeutic option from a pathological standpoint which makes it unique. The workup for autoantibodies to complement pathway regulation and to assess the response of this set of population is a novel approach. The dramatic initial response to plasma exchange for patients with autoantibodies drives home the necessity of studies with etiopathological purview.
